Navigation Links
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Date:2/26/2009

ng cash position, strong partners in GSK and Novartis, and multiple product opportunities to drive future value."

HGS also announced that it has repurchased $106.2 million principal amount of its outstanding convertible debt at a cost of $50.0 million in cash. The repurchase includes $82.9 million principal amount of the Company's 2 1/4% Convertible Subordinated Notes Due October 2011, and $23.3 million principal amount of the Company's 2 1/4% Convertible Subordinated Notes Due August 2012.

"We are pleased that we were able to capitalize on an opportunity to further strengthen our balance sheet by reducing our debt at reasonable prices," said Tim Barabe, Senior Vice President and Chief Financial Officer, HGS. "Our cash position remains strong and is sufficient to take us through the availability of Phase 3 data and the filing of marketing applications for our lead products, while also funding development of our product pipeline."

FINANCIAL RESULTS

HGS reported increased revenues of $48.2 million for the year ended December 31, 2008, compared with revenues of $41.9 million for the same period in 2007. Revenues for 2008 included $35.4 million recognized from the Albuferon agreement with Novartis, and $6.5 million in revenue recognized from the LymphoStat-B agreement with GSK.

The Company reported a net loss for 2008 of $244.9 million ($1.81 per share), compared with a net loss of $262.4 million ($1.95 per share) for 2007. The decreased net loss for 2008 was due primarily to a gain on the sale of CoGenesys stock of $32.5 million ($0.24 per share), partially offset by a decrease in investment income and a charge for impaired investments in debt issued by Lehman Brothers Holdings, Inc., of $6.3 million ($0.04 per share).

Net cash burn for 2008 totaled $244.8 million, compared with $179.9 million in 2007. The increase in net cash burn primarily reflected va
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
3. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
7. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
10. 2008 Human Research Protection Award Recipients Announced
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Calif. , Sept. 22, 2014 Avanir ... that it is offering to sell $200 million of ... Morgan, Deutsche Bank Securities and BofA Merrill Lynch are ... to grant the underwriters a 30-day option to purchase ... shares to be sold in the offering are being ...
(Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
... The U.S. Food and Drug Administration,s (FDA) ... decided today that it could not recommend approval ... the currently available data (13-3); but, voted unanimously ... a reader training program that demonstrates reader accuracy ...
... Medical Simulation Corporation (MSC) will highlight a ... providers at the 2011 International Meeting on Simulation ... MSC,s full-service simulation training and education services are ... all healthcare providers. MSC,s complete line of equipment ...
Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Medical Simulation Corporation to Feature Full Spectrum of Services and Simulation-Based Curriculum at the 11th Annual International Meeting on Simulation in Healthcare 2
(Date:9/22/2014)... On Tuesday, September 16th, 2014, at 8:00 p.m. ... “KC After Dark.” Hosted by top WRNW1 host, ... every Tuesday at 8:00 p.m. EST. WRNW1 had a promotion ... and because of the amazing turnout for their first show, ... 500 callers. , During this comical, yet professional show, ...
(Date:9/22/2014)... September 22, 2014 The Philadelphia 100, ... Greater Philadelphia region each year, is considered a hallmark ... manufacturer MK Precision is proud to announce it has ... MK Precision will attend the Philadelphia 100 ... the premiere business events of the year, as well ...
(Date:9/22/2014)... 2014 (HealthDay News) -- All sexually active women ... common sexually transmitted infections: chlamydia and gonorrhea, according ... Task Force. The task force noted ... 24 years of age and pregnant women. ... noticeable symptoms. As a result, many infections go ...
(Date:9/22/2014)... Amy Norton HealthDay Reporter ... may fare better when newborn intensive care units (NICU) set ... infants, a new study finds. Researchers at one children,s ... and were less distressed when their NICU switched from the ... findings, published online Sept. 22 in the journal Pediatrics ...
(Date:9/22/2014)... seems futuristic, if not impossible. But with a ... researchers at University of California, San Diego School ... an entire, functional eye a reality. , "A ... for vision restoration," said Jeffrey Goldberg, MD, PhD, ... at University of Pittsburg Medical Center and Boston ...
Breaking Medicine News(10 mins):Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:MK Precision Announces Spot on Philadelphia 100 Fastest Growing Companies 2Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Looking ahead: Whole eye transplant under development 2
... The Autism Research Institute states that many of those ... appropriately diagnosed and treated may result in marked improvementATLANTA, ... every 20 seconds in the US. Autism is ... AIDS combined. The Federal Centers for Disease Control ...
... SANTA MONICA, Calif., April 6 Cord Blood America, Inc. ... preservation company ( http://www.cordblood-america.com ) ... to families nationwide and internationally, is pleased to announce that ... long term debt by approximately $750,000, or 12 percent. ...
... place in line at local emergency departments and ... has selected Trevelino/Keller Communications Group, Inc., one of ... launch the company nationally and build out its ... Alabama and Florida -- as it pursues national ...
... a systemic disease or an autoimmune disorder in which the ... of cells called the synovium that lines and lubricates the ... and crippling stiffness, particularly of the hands and feet. It ... mobility and quality of life. RA cannot be confirmed or ...
... solutions provider, is pleased to announce that its entire suite of ... , ... Charlotte, NC (PRWEB) April 6, 2009 -- IQMax, ... that its entire suite of healthcare solutions is available on Blackberry® ...
... high blood pressure and heart disease during a clinical trial for osteoarthritis. ... ... Company, a Bendigo based company who manufactures a topical pain relief lotion ... trial for their flagship product, Elmore Oil., , ,The trial was headed ...
Cached Medicine News:Health News:Alarming Rise in Autism Brings Hundreds of Parents, Researchers and Clinicians Together from Around the World to Atlanta April 17-19, 2009 2Health News:Cord Blood Announces $1.75 Million Reduction in Long Term Debt 2Health News:Imagine No More Waits for Emergency Room Care ... InQuickER Chooses Trevelino/Keller Communications to Launch First Service of Its Kind 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 3Health News:IQMax Delivers Healthcare Solutions to Blackberry Devices 2Health News:Arthritis Trial Leads to Potential Cure for High Blood Pressure 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9CA Broth...
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
...
Medicine Products: